- Home
- BRW vs CRMD Comparison
BRW vs CRMD Comparison
Compare BRW & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | CRMD |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.8M | 876.7M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | BRW | CRMD |
|---|---|---|
| Price | $7.08 | $11.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 222.1K | ★ 2.9M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 15.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | N/A | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | ★ N/A | $5.10 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $7.15 | $5.60 |
| 52 Week High | $8.30 | $17.43 |
Technical Indicators
Market Signals| Indicator | BRW | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 61.66 |
| Support Level | $7.11 | $10.90 |
| Resistance Level | $7.16 | $12.10 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 0.46 | 83.07 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.